IngredientsTetradecylthioacetic acid (TTA) is a synthetic fatty acid used as a nutritional supplement. The compound specifically referred to as alpha-methyl tetradecylthioacetic acid (α-methyl TTA) is a structurally modified derivative of TTA in which an additional methyl group is introduced at the alpha (α) carbon position — the carbon immediately adjacent to the carboxyl group. This modification is distinct from the parent compound TTA and represents one of a class of chemically engineered fatty acid analogues developed primarily for research into peroxisome proliferator-activated receptor (PPAR) biology.
The parent compound, TTA, is comprised of a 16-carbon backbone with an insertion of a sulfur atom in position 3 (β-position) from its carboxyl end. This modification renders TTA unable to undergo complete β-oxidation and increases its biological activity, including activation of peroxisome proliferator-activated receptors (PPARs) with preference for PPARα. The α-methyl derivative builds upon this scaffold by adding methylation at the alpha carbon, producing a compound with further-modified metabolic and receptor-binding properties.
Tetradecyl thioacetic acid (TTA) is a nondietary fatty acid which belongs to the omega-3 class, but is also considered a thia fatty acid as it possesses a sulfur group in the fatty acid chain. It does not have the ability to be β-oxidized due to this, and does not confer to bodily energy requirements.
The chemical name of the parent is commonly written as 3-thiatetradecanoic acid or tetradecylthioacetic acid (CAS 2921-20-2). Alpha-methyl TTA, by contrast, bears the IUPAC-style descriptor 2-methyl-3-thiahexadecanoic acid (or equivalently, α-methyl tetradecylthioacetic acid), reflecting both the α-methyl substitution and the sulfur at the β-position of a 16-carbon fatty acid chain.
Both TTA and its α-methyl derivative are entirely synthetic: they do not occur as natural constituents of any plant, animal, or microbial source. They have no traditional or historical use in any culture or healing system and were first described in the scientific literature in the context of lipid-metabolism and peroxisomal biology research, primarily by the laboratory of Rolf K. Berge and collaborators at the University of Bergen, Norway, beginning in the late 1980s to 1990s.
TTA is used as a nutritional supplement. In commerce, it has appeared in oral capsule formulations. In proprietary weight-loss supplements such as Meltdown®, α-methyl tetradecylthioacetic acid has been included as part of a multi-ingredient proprietary blend alongside caffeine anhydrous, yerba mate extract, and cyclic AMP, among other stimulant-class ingredients. The exact quantity of α-methyl TTA within such proprietary blends is typically not disclosed separately, as it is grouped with other ingredients under a single combined weight.
Standalone TTA supplements have been marketed in capsule form at concentrations of 500 mg per capsule. Novel glycerolipid and phospholipid formulations of TTA have been explored in research settings. In order to improve the biological efficacy of TTA as a PPAR agonist, two novel phospholipid analogue molecules — lyso tetradecylthioacetyl-L-alpha-phosphatidylcholine and di-tetradecylthioacetyl-L-alpha-phosphatidylglycerol — have been developed.
Alpha-methyl TTA and its parent compound TTA have no documented traditional or historical use in any ethnobotanical, Ayurvedic, Traditional Chinese Medicine, or any other pre-scientific medical tradition. These are entirely synthetic chemical entities created in laboratory settings in the modern era. The first characterization of thia fatty acids (3-thia fatty acids) appeared in the biochemical literature in the late 1980s, and TTA in particular emerged as a research compound in the 1990s. The α-methyl derivative was described in the early 2000s as part of systematic chemical structure–activity relationship (SAR) studies of PPAR-activating fatty acid analogues.
The compound therefore belongs to a class of pharmacological research tools and experimental dietary supplements rather than to any tradition of plant-based or food-based medicine. There is no ethnobotanical record, historical pharmacopoeia, or traditional monograph covering this substance.
Tetradecylthioacetic Acid (TTA) is a sulfur-substituted fatty acid analogue known for its hypolipidemic and anti-inflammatory effects, as well as its ability to activate peroxisome proliferator-activated receptors (PPARs). Studies have shown that TTA can influence metabolic processes, lipid metabolism, and mitochondrial function.
TTA is a synthetic fatty acid with a sulfur substitution in the β-position. This modification renders TTA unable to undergo complete β-oxidation and increases its biological activity, including activation of peroxisome proliferator-activated receptors (PPARs) with preference for PPARα.
Alpha-methylated derivatives of TTA showed stronger activation of PPARα, enhancing the expression of target genes involved in fatty acid metabolism. The addition of the methyl group at the alpha carbon appears to increase the affinity and efficacy of the molecule for PPARα above and beyond what is seen with the unmodified parent. TTA activates PPAR subtypes, especially PPARα and PPARγ, with chain lengths up to C14 showing increased activation effects.
The study by Larsen et al. (2005), published in the journal Lipids, systematically investigated sulfur-substituted and α-methylated fatty acids as peroxisome proliferator-activated receptor activators, providing the key structure–activity data establishing α-methyl TTA as a more potent PPARα ligand than unmodified TTA.
All three rodent peroxisome proliferator-activated receptor (PPAR) subtypes were activated by TTA in the ranking order PPARα > PPARδ > PPARγ. In cultured liver cells, TTA acted as a pan-PPAR agonist with predominant PPAR-alpha and PPAR-delta activation at low TTA concentrations. TTA's lipid-lowering effects in the liver do not require PPARα, with PPARδ activation also playing a key role.
Although TTA has physicochemical properties similar to natural fatty acids, the sulfur-substitution blocks β-oxidation of the fatty acid from the carboxyl end. The relatively slow hepatic and renal occurring metabolism of TTA instead involves ω-oxidation followed by partial β-oxidation from the omega end.
This chemical modification still allows TTA to be absorbed in the intestine and transported to the liver where it can act as substrate for desaturation and incorporation into glycerolipids, preferably into the phospholipid fraction.
TTA is a fatty acid analogue lacking the ability to undergo mitochondrial β-oxidation. TTA promotes hepatic proliferation of mitochondria and peroxisomes and also decreases serum triglycerides and cholesterol in animals. Research published in 2013 demonstrated that induction of mitochondrial biogenesis and respiration is associated with mTOR regulation in hepatocytes of rats treated with TTA.
TTA has the ability to attenuate tumor necrosis factor α–mediated endothelial cell activation, further supporting anti-inflammatory effects of this fatty acid, possibly involving both PPAR-α–dependent and independent pathways. TTA suppressed the tumor necrosis factor α–induced expression of vascular cell adhesion molecule 1 (VCAM-1) and interleukin 8 (IL-8) in HUVECs (human umbilical vein endothelial cells).
In CaCo-2 cells, TTA reduces triacylglycerol secretion without affecting the synthesis induced by oleic acid or the general secretory process. Histological analysis of the small intestine revealed a reduced size of lipid droplets in enterocytes of TTA-treated mice, accompanied by increased mRNA expression of fatty acid transporter genes. Expression of the cholesterol efflux pump Abca1 was induced in the small intestine, but not in the liver.
Preclinical evidence (animal and cell studies): Resembling other PPARα agonists, TTA administration to rodents has a pronounced plasma triacylglycerol (TAG) reducing effect. In addition, some hypolipidemic effects of TTA have been demonstrated to be partly PPARα independent, thus supporting the hypothesis that TTA acts as a PPAR pan-ligand activating also PPARγ and δ. In mice fed a high-fat diet, plasma triacylglycerol (TAG) was reduced 3-fold with TTA treatment, concurrent with increase in liver TAG. Total cholesterol was unchanged in plasma and liver. However, TTA promoted a shift in the plasma lipoprotein fractions with an increase in larger HDL particles.
Human clinical evidence (Phase I, healthy volunteers): A Phase I study described the clinical, hematological, and biochemical safety of TTA. A total of 18 healthy volunteers were included. Subjects were randomly assigned into 3 groups according to the daily given dose of TTA: group 1 (200 mg), group 2 (600 mg), and group 3 (1000 mg). TTA was given as a single oral dose for 7 consecutive days. TTA did not induce significant changes in the blood lipids or free fatty acids, but it did result in an increase in plasma concentration of Δ9 desaturated TTA (TTA:1n-8).
Human clinical evidence (type 2 diabetes): TTA was previously demonstrated to improve transport and utilization of lipids and increase mitochondrial fatty acid oxidation in animal and cell studies. An exploratory study of safety and effects of this novel drug in patients with type 2 diabetes mellitus was conducted and the mechanism of action investigated in human cell lines. Sixteen male patients with type 2 diabetes mellitus received 1 g TTA daily for 28 days in an open-labelled study, with measurement of parameters of lipid metabolism, glucose metabolism and safety. The investigators demonstrated for the first time that TTA attenuates dyslipidaemia in patients with type 2 diabetes mellitus, with effects occurring through mechanisms involving PPAR-alpha and PPAR-delta activation, resulting in increased mitochondrial fatty acid oxidation. Total fatty acid levels declined, especially the fraction of the polyunsaturated n-3 fatty acids docosahexaenoic acid (−13%, p = 0.002) and eicosapentaenoic acid (−10%, p = 0.07). Glucose metabolism was not altered and the drug was well tolerated.
Evidence strength: The human evidence for lipid-lowering is preliminary. The type 2 diabetes study involved only 16 male patients in an open-label (unblinded) design without a placebo control, which substantially limits the conclusions that can be drawn. The Phase I healthy volunteer study showed no significant lipid changes. Human evidence is therefore mixed and insufficient to establish efficacy at this time.
Preclinical evidence: TTA is a non-β-oxidizable fatty acid analog which potently regulates lipid homeostasis. In Wistar rats fed a high fat diet, TTA administration completely prevented diet-induced insulin resistance and adiposity. In genetically obese Zucker (fa/fa) rats, TTA treatment reduced the epididymal adipose tissue mass and improved insulin sensitivity. Expression of PPARγ target genes in adipose tissue was unaffected by TTA treatment, whereas the hepatic expression of PPARα-responsive genes encoding enzymes involved in fatty acid uptake, transport, and oxidation was induced. This was accompanied by increased hepatic mitochondrial β-oxidation and a decreased fatty acid/ketone body ratio in plasma.
Evidence strength: Evidence for effects on adiposity and insulin resistance derives entirely from rodent models. No controlled human clinical trials have investigated these outcomes with TTA or α-methyl TTA.
Preclinical evidence: TTA is a hypolipidemic antioxidant with immunomodulating properties involving activation of PPARs and proliferation of mitochondria. A study examined the effect of TTA on the development of atherosclerotic lesions in apolipoprotein E-knockout (apoE-/-) mice fed a high-fat diet containing 0.3% TTA for 12 weeks. These mice displayed significantly less atherosclerotic development versus control. Plasma cholesterol was increased by TTA administration and triacylglycerol levels in plasma and liver were decreased by TTA supplementation, the latter probably due to increased mitochondrial fatty acid oxidation and reduced lipogenesis.
In a rat model of post-myocardial infarction heart failure, TTA had a beneficial effect on cardiac function in post-myocardial infarction heart failure without affecting myocardial remodeling. The data suggest that TTA may improve myocardial function in heart failure, potentially involving its ability to decrease the availability of FFA and increase the myocardial proportion of n-3 PUFA.
Human evidence (HIV-associated dyslipidaemia): Highly active antiretroviral therapy (HAART) often leads to a dramatic improvement in clinical, viral and immunologic parameters in HIV-infected individuals; however, the emergence of long-term side-effects of HAART and in particular dyslipidaemia is increasingly reported. Based on the potential lipid-lowering and immunomodulatory properties of TTA, an investigation was conducted of whether TTA in combination with dietary intervention could modify lipid levels in peripheral blood in HIV-infected patients on HAART. Ten HIV-infected patients on protease inhibitor-based HAART with hyperlipidaemia followed a cholesterol-lowering diet throughout the study period (8 weeks). During the last 4 weeks of the study, all patients received TTA (1 g daily) in addition to the cholesterol-lowering diet. During the TTA phase, the cholesterol-lowering effect was accompanied by a significant reduction in plasma levels of tumour necrosis factor alpha. Studies in peripheral blood mononuclear cells from these patients and in the liver from wild-type mice receiving TTA suggest that the hypolipidemic effects of TTA may involve up-regulation of scavenger and LDL-receptor expression. The pilot study suggests that TTA combined with dietary intervention could be an interesting therapeutic approach in HIV-infected patients on HAART, potentially resulting in both hypolipidaemic and anti-inflammatory effects.
Evidence strength: The HIV-HAART pilot study is very small (n=10), uncontrolled, and confounded by the simultaneous dietary intervention. Results are preliminary and hypothesis-generating only.
In vitro and animal evidence: TTA is a moderate pan-activator of PPARs and has in previous studies showed potential as an antioxidant and anti-inflammatory agent, both through PPAR and non-PPAR mediated mechanisms. In a rat model of dextran sulfate sodium (DSS)-induced colitis, ultrasound measurements showed a significantly reduced colonic wall thickening in the TTA-treated group. TNF-α, IL-1β, and IL-6 were reduced at the protein and mRNA level. TTA-treated rats demonstrated reduced colonic oxidative damage, while inducible nitric oxide synthase 2 mRNA expression was elevated in both the DSS- and TTA+DSS-groups. PPARγ signaling may be involved in the anti-inflammatory response to TTA, as Pparg mRNA expression was significantly upregulated in colon. This study demonstrated that the pan-PPAR agonist TTA reduced colonic oxidative damage and cytokine levels in a rat model of colitis, and its potential to ameliorate colitis should be further explored. Notably, the disease activity index was not improved in the TTA+DSS-group compared to the DSS-group, indicating the effects were biochemical rather than clinically significant in this model.
One study investigating the influence of TTA on persons with HIV currently undergoing anti-viral therapy found a decrease of the circulating inflammatory cytokine TNF-α yet no influence on viral loads in immune cells.
In Atlantic salmon, TTA-supplemented diets significantly reduce mortality during natural outbreaks of viral diseases, suggesting a modulatory role of the immune system.
Evidence strength: Anti-inflammatory evidence is predominantly from animal and cell culture studies. The human evidence from the HIV pilot study is extremely limited. No controlled human trials targeting inflammatory outcomes have been completed.
The fatty acid analogue TTA promotes mitochondrial and peroxisomal proliferation, and may induce oxidative stress and change the growth potential of cancer cells. TTA reduced [³H]thymidine incorporation in the glioma cell lines BT4Cn (rat), D54Mg (human), and GaMg (human) in a dose- and time-dependent manner. The 50% inhibitory TTA doses were approximately 125 μM for BT4Cn and D54Mg cells and 40 μM for GaMg cells after 4 days.
In more detailed mechanistic research, TTA inhibits proliferation of glioma cancer cells through both PPARγ-dependent and PPARγ-independent pathways, of which the latter appears to predominate. In cell culture experiments, the PPARγ-selective ligand BRL49653 moderately inhibited growth of BT4Cn cells, whereas administration of TTA resulted in a marked growth inhibition. Administration of the PPARγ-selective antagonist GW9662 abolished BRL49653-induced growth inhibition, but only marginally reduced the effect of TTA. TTA reduced tumor growth and increased the survival time of rats with implanted BT4Cn tumor. TTA-induced apoptosis in BT4Cn cells, and the administration of TTA led to cytochrome c release from mitochondria and increased the glutathione content in glioma cells.
Evidence strength: All anti-cancer evidence for TTA (and by extension, α-methyl TTA) is from in vitro cell culture and rodent experiments. There are no human clinical trials in oncology. These findings are highly preliminary and exploratory.
Alpha-methyl TTA has appeared in multi-ingredient thermogenic supplement formulations. In a human study using the commercial product Meltdown®, the results indicated that a weight loss supplement containing anhydrous caffeine, synephrine, tetradecylthioacetic acid, yerba mate extract, methylphenylethylamine, yohimbine, and hordenine is effective in increasing acute energy expenditure in young, healthy individuals. Ingestion of this supplement also resulted in significant elevations in heart rate and systolic blood pressure indicating a strong inotropic response. In addition, acute ingestion of this supplement increased tension and confusion among subjects.
Evidence strength: The thermogenic study evaluated a proprietary multi-ingredient blend and cannot attribute any observed effect to α-methyl TTA specifically. This evidence does not support any conclusion about the isolated activity of α-methyl TTA on thermogenesis or body weight.
Based on the published research record, TTA and its α-methyl derivative have been studied in relation to the following body systems and health areas:
The following dosages have been reported in published scientific studies and should not be interpreted as recommendations. Dosages for α-methyl TTA specifically as an isolated compound have not been established in human studies; the dosages below refer to TTA (the parent compound) unless otherwise noted:
Serum concentration pattern of TTA at day 1 showed a 1.5-hour lag time followed by rapid absorption and a slower elimination phase. The median peak values were 2.9 mg/L, 11.5 mg/L, and 11 mg/L in the 200 mg, 600 mg, and 1000 mg dose groups, respectively (P = 0.006).
Few adverse events of mild severity were reported in the Phase I study. No clinically significant changes were observed in the hematological or clinical chemical parameters in blood/urine. The authors concluded that TTA at its highest dose (1000 mg) was well tolerated by humans; however, studies of long-term effects are needed.
In the type 2 diabetes study, glucose metabolism was not altered and the drug was well tolerated. Total fatty acid levels declined, especially the fraction of the polyunsaturated n-3 fatty acids docosahexaenoic acid (−13%, p = 0.002) and eicosapentaenoic acid (−10%, p = 0.07). This reduction in circulating long-chain omega-3 fatty acids at doses used clinically warrants attention, particularly in populations already at risk of omega-3 insufficiency.
A consistent finding in rodent studies is that while TTA reduces plasma triglycerides, it simultaneously increases liver TAG. Plasma triacylglycerol (TAG) was reduced 3-fold with TTA treatment, concurrent with increase in liver TAG. The clinical significance of this hepatic triglyceride accumulation in humans has not been established, as long-term human studies have not been conducted.
In contrast to mammals, high levels of dietary TTA have been reported to induce mortality in Atlantic salmon, but not in Rainbow trout. It has been hypothesized that the mortality may be related to accumulation of TTA metabolites in the kidney at low temperatures. This species difference underscores that metabolic handling of TTA varies across organisms and does not directly predict mammalian or human safety.
When α-methyl TTA was consumed as part of the multi-ingredient Meltdown® supplement, ingestion resulted in significant elevations in heart rate and systolic blood pressure indicating a strong inotropic response. However, as multiple stimulant-class ingredients were present (caffeine, synephrine, yohimbine), these cardiovascular effects cannot be attributed to α-methyl TTA alone.
The human type 2 diabetes study documented a statistically significant reduction in plasma DHA and a trend toward reduced EPA during TTA supplementation. In cultured liver cells, TTA acted as a pan-PPAR agonist with predominant PPAR-alpha and PPAR-delta activation at low TTA concentrations. In myotubes, TTA and a PPAR-delta agonist, but not the PPAR-alpha or PPAR-gamma agonists, increased fatty acid oxidation. Enhanced oxidation of long-chain polyunsaturated fatty acids may partly explain the observed reductions in circulating EPA and DHA.
In human clinical study, there have been mixed observations in preliminary studies. One Phase I study showed no significant changes in blood lipids or free fatty acids and another showed that TTA attenuates dyslipidemia in patients with type 2 diabetes mellitus. The longest human trial conducted with TTA to date was 28 days (the open-label type 2 diabetes study). No long-term controlled human safety or efficacy data exist for TTA or α-methyl TTA.
TTA is used as a nutritional supplement. However, neither TTA nor α-methyl TTA has received approval as a pharmaceutical drug by any major regulatory agency (FDA, EMA, or equivalent). The compound has no monograph in the United States Pharmacopeia (USP), the European Pharmacopoeia, or WHO monographs. It is not reviewed by the NIH Office of Dietary Supplements, NCCIH, or EFSA. The available human evidence base consists of a single Phase I dose-escalation safety study (n=18, 7 days), one open-label metabolic exploratory study in type 2 diabetic men (n=16, 28 days), and one pilot study in HIV/HAART patients (n=10, 4 weeks of TTA). TTA is technically an omega-3 fatty acid and a non-metabolizable fatty acid that cannot be used for energy. Lacking studies in humans at the moment, TTA appears to be a promising future candidate for fat loss and health.
Health conditions that Alpha methyl tetradecylthioacetic acid may help support.
Body systems that Alpha methyl tetradecylthioacetic acid may help support.
Go back